Human phosphatase inhibitor protein

Details Human phosphatase inhibitor protein Human phosphatase inhibitor protein

1999-03-04

2002-08-06

Prouty, Rebecca E. (Department: 1652)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S019000, C530S350000, C514S012200

Reexamination Certificate

active

06428949

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of a novel human phosphatase inhibitor protein and to the use of these sequences in the diagnosis, prevention, and treatment of cancer, AIDS, immunodeficiencies, autoimmune diseases, inflammatory diseases, and proliferative diseases.
BACKGROUND OF THE INVENTION
Major histocompatibility complex (MHC) class II molecule is an essential component of the immune response to foreign antigens. The MHC class II molecule is expressed on the surface of B lymphocytes, macrophages, dendritic cells, and activated T cells (Kaufman, J. F. et al. (1984) Cell 36:1-13). The MHC class II molecule presents a processed foreign antigen at the cell surface to receptors located on competent helper T cells (Lanzavecchia, A. (1985) Nature 314:537-539). Antigens are processed (proteolytically degraded into small peptides) and loaded onto the MHC class II molecules in an acidic, hydrolase-rich lysosome-like cellular compartment prior to transport to the cell surface (Peters, P. J. et al. (1991) Nature 349:669-676). Binding of the MHC class II/antigen complex to the receptor leads to activation of the helper T cells.
MHC class II molecules are heterodimeric glycoproteins composed of an &agr;- and &bgr;-chain (Kaufinan, J. F. et al., supra). Binding of an extracellular region of the MHC class II dimer by T cell receptors in the presence of processed antigen, or by anti-MHC antibodies, is thought to transduce a signal into the cell across the plasma membrane. Cross-linking of MHC class II molecules leads to increased intracellular cAMP levels and translocation of protein kinase C (PKC) to the nucleus in mouse cells (Cambier, J. C. et al. (1987) Nature 327:629-632), and to tyrosine phosphorylation, phosphatidylinositol turnover, increased free intracellular Ca
2+
, and PKC activation in human cells (Mooney, N. A. et al. (1990) J. Immunol. 145:2070-2076; Brick-Ghannam, C. et al. (1991) J. Biol. Chem. 266:24169-24175).
Signal transduction by cross-linked MHC class II molecules implies that an intracellular portion of the dimer plays an essential role and thereby contributes to activation of B cells and helper T cells during the T cell-dependent immune response. Experiments with cell lines expressing truncated forms of the mouse MHC class II molecule support this model and suggest that soluble cytoplasmic proteins interacting with the intracellular domain of the dimer participate in signal transduction (Ostrand-Rosenberg, S. et al. (1991) J. Immunol. 147:2419-2422).
A search for cytoplasmic proteins that interact with the intracellular domain of MHC class II molecules detects two proteins from separate genes that are designated PHAPI and PHAPII. These proteins interact specifically with the intracellular domain of the MHC class II &agr;-chain, but not with the &bgr;-chain or other unrelated proteins (Vaesen, M. et al. (1994) Biol. Chem. Hoppe-Seyler 375:113-126). Sequence analyses indicate that carboxy ends of PHAPI and PHAPII are highly acidic and are similar to the acidic activating domains of transcription factors (Vaesen, M. et al., supra; Ptashne, M. (1988) Nature 335:683-689).
PHAPI has two regularly spaced leucine/isoleucine motifs in the amino terminal region of the protein. These motifs are similar to those found in yeast adenylyl cyclase, human platelet receptor protein, and yeast mitosis dephosphorylation regulator (Vaesen, M. et al., supra; Li, M. et al. (1996) Biochemistry 35:6998-7002). PHAPI also has a nuclear localization signal in its carboxy terminus and significant amounts are detected both in the nucleus and diffusely distributed throughout the cytoplasm (Vaesen, M. et al., supra).
Additional analysis shows that PHAPI is identical to I
1
PP2A
, a specific and potent inhibitor of the protein phosphatase 2A (PP2A; Li, M. et al., supra). PP2A is an important protein serine/threonine phosphatase that is involved in the regulation of diverse mammalian cell processes including reentry of quiescent cells into the cell cycle (Cohen, P. (1989) Annu. Rev. Biochem. 58:453-508; Shenolikar, S. and A. C. Nairn (1991) Adv. Second Messenger Phosphoprot. Res. 23:1-121; Mumby, M. C. and G. Walter (1993) Physiol. Rev. 73:673-699).
The discovery of polynucleotides encoding the human phosphatase inhibitor protein, and the molecules themselves, provides a means to investigate signal transduction, mitogenesis and cellular proliferation, and the immune response. Discovery of molecules related to phosphatase inhibitor protein satisfies a need in the art by providing new diagnostic or therapeutic compositions useful in the diagnosis, prevention, and treatment of cancer, AIDS, immunodeficiencies, autoimmune diseases, inflammatory diseases, and proliferative diseases.
SUMMARY OF THE INVENTION
The present invention features a novel human phosphatase inhibitor protein hereinafter designated HPIP and characterized as having similarity to PHAPI (I
1
PP2A
).
Accordingly, the invention features a substantially purified HPIP having the amino acid sequence shown in SEQ ID NO:1.
One aspect of the invention features isolated and substantially purified polynucleotides that encode HPIP. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.
The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.
The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode HPIP. The present invention also features antibodies which bind specifically to HPIP, and pharmaceutical compositions comprising substantially purified HPIP. The invention also features the use of agonists and antagonists of HPIP.


REFERENCES:
Kaufman, J.F. et al., “The Class II Molecules of the Human and Murine Major Histocompatibility Complex”,Cell36(1) :1-13 (1984).
Lanzavecchia, A., “Antigen-specific interaction between T and B cells”,Nature314 (6011) :537-539 (1985).
Peters, P.J. et al., “Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments”,Nature349 (6311) :669-676 (1991).
Cambier, J.C. et al., “Ia binding ligands and cAMP stimulate nuclear translocation of PKC in B lymphocytes”Nature327 (6123) :629-632 (1987).
Mooney, N.A. et al., “Early biochemical events after MHC class II-mediated signaling on human B lymphocytes”,J. Immunol. 145 (7) :2070-2076 (1990).
Brick-Ghannam, C. et al., “Protein Kinase C (PKC) Activation via Human Leucocyte Antigen Class II Molecules”,J. Biol. Chem. 266 (35) :24169-24175 (1991).
Ostrand-Rosenberg, S. et al., “Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule”,J. Immunol. 147 (7) :2419-2422 (1991).
Vaesen, M. et al., “Purification and Characterization of Two Putative HLA Class II Associated Proteins: PHAPI and PHAPII”Biol. Chem. Hoppe-Seyler375:113-126 (1994) (Accession G403007).
Ptashne, M., “How eukaryotic transcriptional activators work”,Nature335 (6192) :683-689 (1988).
Li, M. et al., “Molecular Identification of I1PP2A, a Novel Potent Heat-Stable Inhibitor Protein of Protein Phosphatase 2A”,Biochemistry35:6998-7002 (1996).
Cohen, P., “The structure and regulation of protein phosphatases”,Annu. Rev. Biochem. 58:453-508 (1989).
Mumby, M.C. and Walter, G., “Protein Serine/Threonine Phosphatases: Structure, Regulation, and Functions in Cell Growth”,Physiol. Rev. 73:673-699 (1993).
Vaesen, M. et al., (Direct Submission), GenBank Sequence Database (Accession G1498225), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland 20894 Sep. 10, 1996.
Amick, G.D. et al., “Protein phosphatase 2 is a specific protamine-kinase-inactivating phosphatase”,Biochem. J. 287 (Pt3):1019-102

Affiliated with

Also associated with

Rating

Human phosphatase inhibitor protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human phosphatase inhibitor protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human phosphatase inhibitor protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2971543